Catalent Expert Appointed to the United States Pharmacopoeia (USP) Advisory Panel on Liquid Filled Gelatin Capsules
Somerset, NJ, June 28, 2010 — Stephen Tindal, Director, Softgel Formulation & Operations for Catalent Pharma Solutions has been accepted as a member of the United States Pharmacopoeia (USP) advisory panel focusing on liquid filled gelatin capsules. His newly appointed responsibilities include collaboration with industry experts to provide guidance on revisions to USP monographs and chapters concerning soft gelatin capsules. One area of work for the Advisory Panel will be on dissolution testing of liquid filled gelatin capsules for prescription, over–the–counter medicines, and other healthcare products manufactured or sold in the United States. The USP sets standards for the quality, purity, strength, and consistency of these products that are critical to the public health. The USP's standards are recognized and used in more than 130 countries around the globe.
“It is an honor to be recognized as a technical expert in the manufacture of soft gelatin capsules. Catalent’s continued commitment to the softgel technology builds on the R.P. Scherer heritage of over 75 years expertise and innovation in softgel development and manufacturing. I look forward to supporting the USP’s mission to improve the health of people around the world through public standards and related programs that help ensure the quality, safety, and benefit of medicines and foods” says Mr. Tindal.
Mr. Tindal joined Catalent 23 years ago, and in 2003 he and his family relocated from England to Catalent’s corporate headquarters in Somerset, New Jersey, where he oversees Softgel Formulation & Operations. Mr. Tindal holds a B.Sc. Honors Degree in Chemistry & Analytical Science from Loughborough University, England.
Mr. Tindal joins Catalent’s Vice President of Quality, Mary Foster, Pharm.D, who currently serves as the Chair of the USP Packaging, Storage and Distribution Expert Committee for the 2010-2015 USP cycle (PSD EC). Dr. Foster served as a member of the 2005-2010 USP PSD EC and currently serves on the USP Advisory Panel for bulk pharmaceutical excipients.
Headquartered in Somerset, New Jersey, Catalent Pharma Solutions is a leading provider of advanced dose form and packaging technologies, and development, manufacturing and packaging services for pharmaceutical, biotechnology and consumer healthcare companies in nearly 100 countries. Catalent applies its local market expertise and technical creativity to advance treatments, change markets and enhance patient outcomes. Catalent employs approximately 9,000 people at 30 facilities worldwide and in fiscal 2009 generated more than $1.6 billion in annual revenue.